Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients
- First Online:
- 129 Downloads
Atypical antipsychotic drugs are classically associated with lower propensity to extrapyramidal symptoms (EPS) and hyperprolactinemia than typical antipsychotic drugs. It has not been clarified why some atypical antipsychotic drugs, such as amisulpride, induce prolactin plasma concentration (PRL) elevation, but little EPS. Previous studies have found an association between striatal D2/D3 receptor occupancy and PRL in typical antipsychotic treated patients suggesting that PRL is a marker of central D2/D3 receptors blockade.
We have evaluated the relationship between PRL and central (striatum, temporal cortex and thalamus) D2/D3 receptor occupancy in amisulpride treated schizophrenic patients.
Single photon emission tomography (SPET) and [123I]-epidepride were used to determine D2/D3 receptor occupancy in eight amisulpride treated patients. PRL was measured concurrently with the scans.
The mean PRL was 1166 (range 499–1892 mIU/l) for a mean amisulpride dose of 406 mg/day (range 150–600 mg/day). Amisulpride plasma concentration and central D2/D3 receptor occupancy were positively correlated (r=0.83–0.89, df=4, P<0.05). No significant correlations were observed between PRL and amisulpride (daily dose or plasma concentration, P>0.05), or between PRL and central D2/D3 receptor occupancy (P>0.05).
Our findings show that amisulpride-induced hyperprolactinemia is uncoupled from central D2/D3 receptor occupancy. Amisulpride has poor blood–brain barrier penetration and reaches much higher concentration at the pituitary, which is outside the blood–brain barrier. Higher D2/D3 receptor occupancy at the pituitary gland than at central regions is a possible explanation for amisulpride PRL elevation with low EPS. Further studies evaluating pituitary D2/D3 receptor occupancy in vivo are necessary to confirm this hypothesis.
KeywordsProlactin Antipsychotic agents Atypical antipsychotic Neuroleptic Dopamine receptor D2-dopamine Schizophrenia SPECT [123I]-epidepride Amisulpride Photon emission tomography
- Alcohol Drug Abuse, and Mental Health Administration (1974) Abnormal involuntary movement scale (AIMS). Department of Health, Education and Welfare, Washington D.C.Google Scholar
- Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS (2003a) Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413–1420CrossRefPubMedGoogle Scholar
- Invitti C, Danesi L, Dubini A, Cavagnini F (1998) Neuroendocrine effects of chronic administration of sodium valproate in epileptic patients. Acta Endocrinol 118:381–388Google Scholar
- Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35:1503–1519Google Scholar
- Kapur S, Langlois X, Vinken P, Megens AA, de Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129–1134CrossRefPubMedGoogle Scholar
- Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276Google Scholar
- Monteleone P, Maj M, Ariano MG, Iovino M, Fiorenza L, Steardo L (1998) Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Psychopharmacology 96:223–226Google Scholar
- Overall J, Gorham D (1962) The brief psychiatric rating scale. Psychol Rep 10:799–812Google Scholar
- Rao ML, Brown WA (1987) Stability of serum neuroleptic and prolactin concentrations during short-term and long-term treatment of schizophrenic patients. Psychopharmacology 93:237–242Google Scholar
- Rivera JL, Lal S, Ettigi P, Hontela S, Muller HF, Friesen HG (1976) Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5:273–282Google Scholar
- Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11–19Google Scholar
- Talairach J, Tourneaux P (1988) Co-planar stereotactic atlas of the human brain. Thieme, New YorkGoogle Scholar